Role of antiplatelet therapy in the durability of hemodialysis access
Antiplatelet therapy (APT) is often used on anecdotal grounds to improve vascular access patency. The aim of this study was to assess the role of APT in hemodialysis (HD) patients undergoing arteriovenous fistula (AVF) or graft (AVG) placement.
All patients in a large HD vascular qualitative initiative database (2011–2017) were included and divided into no antiplatelet therapy (no-APT) vs. any APT [aspirin (ASA) or P2Y12 inhibitors (PI)]. Multivariate [logistic (MLR) and Cox (MCR) regression] analyses were used as appropriate.
A total of 24,847 patients undergoing HD access creation were identified (78% AVF). APT was noted among 49 and 46% of AVG and AVF patients, respectively. In MLR analysis, patients on no-APT vs. APT had a 12-fold increased risk of in-hospital mortality (odds ratio (OR) 11.79, [95% confidence interval 5.30–26.26]) and the risk of developing steal syndrome was higher among patients discharged on APT (OR 1.81, [1.19–2.76]). In patients undergoing AVF, primary patency (PP) was similar between APT and no-APT. However, in patients undergoing AVG, PP rates at 12 months were significantly higher for APT: ASA (47 vs. 41%) and PI (51 vs. 41%) than for no-APT (p = 0.008). At MCR analysis, the loss of PP at 12 months was 13% lower in ASA users (hazard ratio (HR) 0.87, [0.77–0.97], p = 0.02) and 24% lower in PI users (HR 0.76, [0.57–0.99], p = 0.046) compared to no-APT.
In a large national database, we showed that antiplatelet therapy was associated with lower in-hospital mortality. Aspirin and P2Y12-inhibitor use among AVG patients demonstrated improved PP rates compared to no antiplatelet therapy. We recommend the use of antiplatelet therapy especially in patients on AVG.
KeywordsAVF AVG Aspirin Clopidogrel
No special funding was obtained to complete this study.
Compliance with ethical standards:
Conflict of interest
The authors declare that they have no competing interests.
Research involving human participants and/or animals
This article does not contain any studies with human participants performed by any of the authors.
VQI database contains de-identified data, the need for patient informed consent was waived and institution review board (IRB) approval was exempted by the IRB.
- 3.The national kidney foundation kidney disease outcomes quality initiative. https://www.kidney.org/professionals/guidelines. Updated 2016. Accessed 24 March 2017
- 18.Osborn G, Escofet X, Da Silva A (2008) Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev 4:CD002786Google Scholar
- 28.Aspirin and subclavian steal syndrome—from FDA reports. eHealthMe Personalized Health Information Web site. https://www.ehealthme.com/ds/aspirin/subclavian-steal-syndrome/. Updated 2017. Accessed 18 Dec 2017